Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: Report of the pivotal phase 2 study

Cancer

Volumn 115, Issue 15, 2009, Pages 3475-3482

  Rodriguez, M A ^a   Pytlik, Robert ^b   Kozak, Tomas ^b   Chhanabhai, Mukesh ^c   Gascoyne, Randy ^c   Lu, Biao ^d   Deitcher, Steven R ^d   Winter, Jane N ^e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Hana Biosciences   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

NHL; Vincristine liposomes; Vincristine sulfate

Indexed keywords

ERYTHROPOIETIN; MARQIBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; VINCRISTINE SULFATE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIPOSOMAL DELIVERY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEAKNESS; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIPOSOMES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; RETREATMENT; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 68149156436     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24359     Document Type: Article

References (13)

1. Webb MS, Saltman DL, Connors JM, Goldie JH. A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2002;43:975-982.
2. Gidding CE, Kellie SJ, Kamps WA, de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol. 1999;29:267-287.
3. Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol. 2001;1:370-377.
4. Kellie SJ, Koopmans P, Earl J, et al. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer. 2004;100:2637-2643.
5. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin- cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72:896-904.
6. Webb MS, Logan P, Kanter PM, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 1998;42:461-470.
7. Krishna R, Webb MS, St Onge G, Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001;298:1206-1212.
8. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361.
9. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
10. Rowinsky EK, Tolcher AW. Antimicrotubule agents. In: DeVita Jr VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001:431-452.
11. Rodriguez MA, Sarris A, East K, et al. A phase II study of liposomal vincristine in CHOP with rituximab for the elderly patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol. 2002;21:284a. Abstract 1132.
12. Rodriguez MA, Sarris A, East K, et al. A phase II study of liposomal vincristine in CHOP with rituximab for patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL): a safe and effective combination [abstract]. Blood. 2002;100:92a. Abstract 338.
13. Rodriguez MA, Dang NH, Fayad L, et al. Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): follow-up results of a phase II study [abstract]. Presented at 2004 ASCO Annual Meeting; June 5, 2004; New Orleans, LA. Abstract 8080.